INSITRO
Live / Allowed — Notice of allowance issued (as of 25 Nov 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 18 Dec 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98910353
- Mark type
- Design + words
- Filed
- 18 Dec 2024
- Published for opposition
- 30 Sept 2025
- Attorney of record
- Ted D. Karr
Goods and services
- Class 001 — Chemicals: Chemical and biological reagents for scientific research, drug discovery, and drug development; laboratory chemicals and solutions for research purposes, excluding those for medical use, namely, reagents supporting artificial intelligence-driven workflows and machine learning applications
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for human and veterinary use for the treatment and prevention of diseases, namely, human metabolic diseases, human neurological diseases, human ophthalmological diseases, and human genetic diseases.
- Class 009 — Scientific and electric apparatus: Laboratory automation systems comprising scientific laboratory research apparatus for screening cells and molecules for understanding disease causes and mechanisms, and recorded software controlling the apparatus, for scientific research, drug discovery, and drug development; Artificial intelligence (AI) and machine learning (ML) platforms, namely, recorded software platforms for experimental data generation for scientific and laboratory applications for scientific and medical research; digital health solutions, namely, downloadable software for integrating data-driven medical insights.
- Class 042 — Scientific and technological services: Scientific and technological research and development services in the fields of drug discovery, pharmaceutical development, and biotechnology; Platform as a Service featuring artificial intelligence (AI) and machine learning (ML) software platforms for drug discovery, pharmaceutical development, and biotechnology for scientific and medical research; Development of computer software, for drug discovery, genomics, and data analysis; laboratory research services in the field of pharmaceuticals, using automation, high-throughput experimentation, and data modeling software as a service (SaaS) featuring software for AI-powered drug discovery, predictive modeling, and biological data analysis; consulting services in computational biology and AI-driven drug discovery; Medical research services and consulting services in the field of medical research; drug discovery and development support services from a medical perspective, namely, pharmaceutical drug development services; providing medical information and consultancy, namely, providing information and consulting in the field of medical research, related to therapeutic research and development; provision of medicine in the field of diseases, namely, developing treatments for unmet medical needs.
- Class 044 — Medical, beauty and agricultural services: Personalized medicine services, namely, making recommendations for medical diagnostic tests and therapeutic recommendations to patients; healthcare services utilizing artificial intelligence for disease prediction, patient stratification, and management; medical analysis services for diagnostic and treatment purposes of patients; healthcare services; medical treatment services for diseases; healthcare advisory services; pharmaceutical advice; medical clinic services; medical advice for individuals with diseases
Owner
- Insitro, Inc., South San Francisco, CA, US
- Insitro, Inc., South San Francisco, CA, US
Prosecution history
- 25 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Sept 2025 — PUBLISHED FOR OPPOSITION
- 24 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 28 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 27 Aug 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 28 Jul 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 28 Jul 2025 — FINAL REFUSAL E-MAILED
- 28 Jul 2025 — FINAL REFUSAL WRITTEN
- 24 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 24 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Apr 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED